Engineered Human FTO Enzymes for Selective N6-Methyladenosine (m6A) Demethylation and Selective N6,2'-O-dimethyladenosine (m6Am) Demethylation
These tools provide a complete toolkit to independently switch individual RNA methylation states on and off
Background
RNA modifications like N6-methyladenosine (m6A) and N6,2’-O-dimethyladenosine (m6Am) are vital regulators of the eukaryotic transcriptome, influencing many processes from mRNA splicing and stability to translation and export. These RNA modifications are two of the most abundant and clinically significant, particularly in leukemia and glioblastoma progression. The naturally occurring FTO enzyme acts as an eraser for both modifications, helping to regulate their biological functions and playing a role in the progression of human cancers. Because current research tools rely on this wild-type enzyme, scientists cannot use FTO to selectively erase m6Am without also affecting m6A modifications and vice versa. This cross-reactivity makes it impossible to decouple their individual downstream effects and understand the specific roles of FTO-mediated demethylation, creating a major experimental bottleneck in molecular biology and cancer research.
Technology
To help address this hurdle, University of Delaware researchers have developed two complementary, engineered human FTO demethylase variants featuring non-natural amino acid substitutions that fundamentally rewrite FTO enzyme substrate specificity. UD26-58 introduces specific mutations at residue L203 (L203X, such as L203A) to create a recombinant enzyme that selectively erases m6Am RNA modifications while completely eliminating the enzyme’s ability to act upon m6A. Conversely, UD26-15 utilizes targeted substitutions (L109X, H232X, and W278X) to achieve the exact opposite effect, selectively removing m6A modifications. Both engineered variants function as highly stable, non-natural biochemical tools that can be deployed for precise in vitro RNA treatments or integrated into in vivo cell-based assays via standard genetic transfection. These tools provide a complete toolkit to independently switch individual RNA methylation states on and off. These technologies provide the first selective system to independently isolate and erase specific chemical marks on eukaryotic mRNA.
Benefits
-
Epitranscriptomic Precision: Enables the targeted removal of either m6A or m6Am modifications independently without causing unwanted cross-reactivity.
-
Disease Modeling & Target Discovery: Allows researchers to definitively isolate and map the distinct biological roles of m6A versus m6Am, enabling labs to pinpoint the exact molecular mechanisms driving glioblastoma and acute myeloid leukemia.
-
Assay Versatility: Serves as a robust, specialized tool optimized for both cell-free in vitro biochemical treatments and complex, transfected in vivo cellular assays.
Applications
-
Oncology Drug Discovery & Target Validation: Screening and mapping epitranscriptomic pathways to identify novel therapeutic targets for FTO-driven malignancies.
-
Molecular Biology & Epitranscriptomic Research: Advanced academic and industrial laboratory reagents for high-resolution RNA functional analysis and gene expression mapping.
-
High-Throughput Assay Kits: Commercialized in vitro RNA modification and analysis kits.
Additional info
Engineered human FTO demethylase variants feature mutations at residue L203 (L203X, such as L203A) that alter substrate specificity. These recombinant enzymes selectively disrupt the demethylation of N6-methyladenosine (m6A) while preserving catalytic removal of N6,2’-O-dimethyladenosine (m6Am) on eukaryotic RNA. This selectivity enables precise in vitro RNA modification and cellular assays to dissect distinct m6A versus m6Am regulatory mechanisms in malignancies such as glioblastoma and acute myeloid leukemia.